After The Wall Street Journal reported that Air Methods (AIRM) is in the early stages of selling itself, KeyBanc says that a sale of the company "would at least attract initial interest from both financial and strategic buyers." However, the firm is unsure as to whether a deal would close, given what it sees as Air Methods' "operational challenges." KeyBanc estimates that "a non-strategic buyer" of Air Methods could pay in the low to mid $40s per share for the stock. However, it thinks that Air Medical Group Holdings and KKR could offer a meaningfully higher price, given the $30M-$40M in synergies thatit estimates could be realized by such a deal. KeyBanc raised its price target on Air Methods to $45 from $36 and keeps an Overweight rating on it.